Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.040
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
Next >
OKYO Pharma CEO Interview to Air on Bloomberg TV
August 23, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
August 23, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 23, 2024
Via
ACCESSWIRE
OKYO Pharma Announces Chairman Acquires Shares
August 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 15, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Participation in May 2024 Investor Conferences
May 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
April 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
April 02, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
March 20, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023
Top-line Efficacy and Safety Data on Track for Release in December 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
October 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
October 09, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
October 05, 2023
Via
AB Newswire
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 15, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Announces Withdrawal of Public Offering
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Public Offering of Ordinary Shares
September 13, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
September 08, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.